APA (7th ed.) Citation

Aslam, R., Richards, C. E., Fay, J., Hudson, L., Workman, J., Lee, C. L., . . . Hennessy, B. T. (2024). Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models. International Journal of Molecular Sciences, 25(24), 13264. https://doi.org/10.3390/ijms252413264

Chicago Style (17th ed.) Citation

Aslam, Razia, et al. "Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models." International Journal of Molecular Sciences 25, no. 24 (2024): 13264. https://doi.org/10.3390/ijms252413264.

MLA (9th ed.) Citation

Aslam, Razia, et al. "Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models." International Journal of Molecular Sciences, vol. 25, no. 24, 2024, p. 13264, https://doi.org/10.3390/ijms252413264.